Immune Checkpoint Molecules—Inherited Variations as Markers for Cancer Risk
Open Access
- 14 January 2021
- journal article
- review article
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 11
Abstract
In recent years, immunotherapy has been revolutionized by a new approach that works by blocking receptors called immune checkpoints (IC). These molecules play a key role in maintaining immune homeostasis, mainly by suppressing the immune response and by preventing its overactivation. Since inhibition of the immune response by IC can be used by cancer to avoid recognition and destruction by immune system, blocking them enhances the anti-tumor response. This therapeutic approach has brought spectacular clinical effects. The ICs present heterogeneous expression patterns on immune cells, which may affect the effectiveness of immunotherapy. The inherited genetic variants in regulatory regions of ICs genes can be considered as potential factors responsible for observed inter-individual differences in ICs expression levels on immune cells. Additionally, polymorphism located in exons may introduce changes to ICs amino acid sequences with potential impact on functional properties of these molecules. Since genetic variants may affect both expression and structure of ICs, they are considered as risk factors of cancer development. Inherited genetic markers such as SNPs may also be useful in stratification patients into groups which will benefit from particular immunotherapy. In this review, we have comprehensively summarized the current understanding of the relationship between inherited variations ofCTLA-4, PDCD1,PD-L1, BTLA,TIM-3, andLAG-3genes in order to select SNPs which can be used as predictive biomarkers in personalized evaluation of cancer risk development and outcomes as well as possible response to immunotherapy.Keywords
Funding Information
- Narodowe Centrum Nauki
This publication has 222 references indexed in Scilit:
- TIM polymorphisms—genetics and functionGenes & Immunity, 2011
- Variations in Suppressor Molecule CTLA-4 Gene Are Related to Susceptibility to Multiple Myeloma in a Polish PopulationPathology and Oncology Research, 2011
- Common single nucleotide polymorphisms in immunoregulatory genes and multiple myeloma risk among women in ConnecticutAmerican Journal of Hematology, 2010
- Genetic Variants in T Helper Cell Type 1, 2 and 3 Pathways and Gastric Cancer Risk in a Polish PopulationJapanese Journal of Clinical Oncology, 2008
- Analysis of single nucleotide polymorphisms in the FAS and CTLA-4 genes of peripheral T-cell lymphomasJournal of Hematopathology, 2008
- New approach reveals CD28 and IFNG gene interaction in the susceptibility to cervical cancerHuman Molecular Genetics, 2008
- FASTSNP: an always up-to-date and extendable service for SNP function analysis and prioritizationNucleic Acids Research, 2006
- Association ofCTLA4 polymorphism with regulatory T cell frequencyEuropean Journal of Immunology, 2005
- BTLA is a lymphocyte inhibitory receptor with similarities to CTLA-4 and PD-1Nature Immunology, 2003
- Association of the T-cell regulatory gene CTLA4 with susceptibility to autoimmune diseaseNature, 2003